Jijie Gu
Overview
Explore the profile of Jijie Gu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang S, Zhang W, Yang B, Zhang X, Fang J, Rui H, et al.
Antib Ther
. 2024 Jul;
7(3):189-198.
PMID: 39036070
The manufacturability assessment and optimization of bispecific antibodies (bsAbs) during the discovery stage are crucial for the success of the drug development process, impacting the speed and cost of advancing...
2.
Liu H, Su H, Wang F, Dang Y, Ren Y, Yin S, et al.
Cell Rep
. 2023 Mar;
42(3):112275.
PMID: 36943864
Enhancing chemosensitivity is one of the largest unmet medical needs in cancer therapy. Cyclic GMP-AMP synthase (cGAS) connects genome instability caused by platinum-based chemotherapeutics to type I interferon (IFN) response....
3.
Zhang W, Wang H, Feng N, Li Y, Gu J, Wang Z
Antib Ther
. 2023 Jan;
6(1):13-29.
PMID: 36683767
Developability refers to the likelihood that an antibody candidate will become a manufacturable, safe and efficacious drug. Although the safety and efficacy of a drug candidate will be well considered...
4.
Nie S, Wang Z, Moscoso-Castro M, DSouza P, Lei C, Xu J, et al.
Antib Ther
. 2021 Apr;
3(1):18-62.
PMID: 33928225
A bispecific antibody (bsAb) is able to bind two different targets or two distinct epitopes on the same target. Broadly speaking, bsAbs can include any single molecule entity containing dual...
5.
Wang R, Graham S, Sun N, McCarthy D, Peng R, Erickson J, et al.
PLoS One
. 2020 Mar;
15(3):e0228221.
PMID: 32155151
Inflammatory bowel diseases (IBD) are complex, multifactorial disorders characterized by chronic relapsing intestinal inflammation. IBD is diagnosed around 1 in 1000 individuals in Western countries with globally increasing incident rates....
6.
Li Y, Hickson J, Ambrosi D, Haasch D, Foster-Duke K, Eaton L, et al.
Mol Cancer Ther
. 2018 Mar;
17(5):1039-1050.
PMID: 29592882
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a...
7.
Bardwell P, Staron M, Liu J, Tao Q, Scesney S, Bukofzer G, et al.
Protein Cell
. 2017 Jun;
9(1):121-129.
PMID: 28585177
Novel biologics that redirect cytotoxic T lymphocytes (CTLs) to kill tumor cells bearing a tumor associated antigen hold great promise in the clinic. However, the ability to safely and potently...
8.
Ding K, Eaton L, Bowley D, Rieser M, Chang Q, Harris M, et al.
MAbs
. 2016 Dec;
9(2):269-284.
PMID: 27929753
Exudative age-related macular degeneration (AMD) is the most common cause of moderate and severe vision loss in developed countries. Intraocular injections of vascular endothelial growth factor (VEGF or VEGF-A)-neutralizing proteins...
9.
Gu J, Yang J, Chang Q, Liu Z, Ghayur T, Gu J
PLoS One
. 2015 May;
10(5):e0124135.
PMID: 25997020
Epidermal growth factor receptor (EGFR) and receptor tyrosine-protein kinase 3 (ErbB3) are two well-established targets in cancer therapy. There is significant crosstalk among these two receptors and others. To block...
10.
Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, et al.
PLoS One
. 2014 May;
9(5):e97292.
PMID: 24824849
Inhibiting ErbB2 signaling with monoclonal antibodies (mAbs) or small molecules is an established therapeutic strategy in oncology. We have developed anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig) proteins that capture the...